Cigna faces lawsuit alleging inflated home healthcare charges

A policyholder alleged Cigna artificially inflated home healthcare prices to pocket consumers’ overpayments, Bloomberg BNA reports.

Advertisement

The plaintiff filed a lawsuit against Cigna Health & Life Insurance Co. Oct. 6 in a Connecticut federal court. The lawsuit claims Bloomfield, Conn.-based Cigna violated the Employee Retirement Income Security Act by implementing a billing scheme through its policies with benefit managers such as Hartford, Conn.-based CareCentrix. Under the scheme, benefit managers charged consumers too much for co-payments, coinsurance and deductibles and then pocketed the difference, the lawsuit alleges.

For example, the plaintiff claimed Cigna charged nearly 350 percent more than required for a disposable filter used to treat sleep apnea. The policyholder claims he purchased the filter from a CareCentrix provider for $25.68 as part of his deductible. However, the provider allegedly had a contract with Cigna and CareCentrix to charge $7.50 for the filter, Bloomberg BNA reports. The plaintiff argues Cigna secretly collected the remaining $18.18.

The plaintiff seeks class treatment for the lawsuit for thousands of other plan members.

A Cigna spokesperson told Bloomberg BNA the insurer does not comment on litigation. 

More articles on payer issues:
The 23 Medicare plans receiving 5 stars from CMS
Cleveland Clinic enters third integrated payer partnership since June, this time with Anthem
21% of health plan members regularly use insurer’s online portal

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.